{"abstract":"National Institute of Diabetes and Digestive and Kidney Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the SUPPLEMENTARY INFORMATION section of this notice to Kantum Pharma Inc. (Kantum), located in Boston, Massachussets.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2021/05/24/2021-10816.html","cfr_references":[],"citation":"86 FR 27858","comment_url":null,"comments_close_on":"2021-06-08","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Institute of Diabetes and Digestive and Kidney Diseases' Technology Advancement Office on or before June 8, 2021 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2021-10816","effective_on":null,"end_page":27859,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2021/05/24/2021-10816.xml","html_url":"https://www.federalregister.gov/documents/2021/05/24/2021-10816/prospective-grant-of-an-exclusive-patent-license-p2y14-receptor-antagonists-to-treat-kidney-and-lung","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2021-10816?publication_date=2021-05-24","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2021-05-24/2021-10816/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":151,"last_updated":"2026-07-27 20:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2021-05-24/pdf/2021-10816.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2021-10816.pdf?1621601122","publication_date":"2021-05-24","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2021/05/24/2021-10816.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T01:25:23Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":27858,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: P2Y14 Receptor Antagonists To Treat Kidney and Lung Inflammation","toc_doc":"P2Y14 Receptor Antagonists to Treat Kidney and Lung Inflammation","toc_subject":"Prospective Grant of an Exclusive Patent License:\n","topics":[],"type":"Notice","volume":86}